Dashboard
1
Poor Management Efficiency with a low ROCE of 17.19%
- The company has been able to generate a Return on Capital Employed (avg) of 17.19% signifying low profitability per unit of total capital (equity and debt)
2
The company is Net-Debt Free
3
Poor long term growth as Net Sales has grown by an annual rate of 19.05% and Operating profit at 24.09% over the last 5 years
4
The company has declared Negative results for the last 3 consecutive quarters
5
With ROE of 14.31%, it has a fair valuation with a 2.82 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
CNY 8,142 Million (Mid Cap)
20.00
NA
1.65%
0.04
14.31%
3.00
Revenue and Profits:
Net Sales:
439 Million
(Quarterly Results - Jun 2026)
Net Profit:
95 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
0.45%
0%
0.45%
6 Months
-18.13%
0%
-18.13%
1 Year
-9.89%
0%
-9.89%
2 Years
-0.8%
0%
-0.8%
3 Years
-6.29%
0%
-6.29%
4 Years
-8.69%
0%
-8.69%
5 Years
46.12%
0%
46.12%
Aurisco Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
19.05%
EBIT Growth (5y)
24.09%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
0.01
Sales to Capital Employed (avg)
0.49
Tax Ratio
13.26%
Dividend Payout Ratio
30.55%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
16.96%
ROE (avg)
13.03%
Valuation key factors
Factor
Value
P/E Ratio
20
Industry P/E
Price to Book Value
2.82
EV to EBIT
16.14
EV to EBITDA
13.32
EV to Capital Employed
2.75
EV to Sales
4.61
PEG Ratio
19.68
Dividend Yield
1.76%
ROCE (Latest)
17.02%
ROE (Latest)
14.31%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
Bullish
Bollinger Bands
Sideways
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - YoY
Jun'26
Jun'25
Change(%)
Net Sales
439.10
420.00
4.55%
Operating Profit (PBDIT) excl Other Income
172.50
153.20
12.60%
Interest
8.80
8.50
3.53%
Exceptional Items
-1.40
0.60
-333.33%
Consolidate Net Profit
94.80
115.50
-17.92%
Operating Profit Margin (Excl OI)
289.80%
301.70%
-1.19%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2026 is 4.55% vs 6.33% in Jun 2025
Consolidated Net Profit
YoY Growth in quarter ended Jun 2026 is -17.92% vs 8.55% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
1,689.10
1,471.20
14.81%
Operating Profit (PBDIT) excl Other Income
657.50
474.20
38.65%
Interest
35.60
16.80
111.90%
Exceptional Items
4.40
2.30
91.30%
Consolidate Net Profit
449.20
354.80
26.61%
Operating Profit Margin (Excl OI)
313.30%
261.00%
5.23%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 14.81% vs 16.93% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 26.61% vs 22.73% in Dec 2024
About Aurisco Pharmaceutical Co., Ltd. 
Aurisco Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available
Footer loading






